<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102593</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1603.</org_study_id>
    <secondary_id>2016-003038-26</secondary_id>
    <nct_id>NCT03102593</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>arGEN-X BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>arGEN-X BVBA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics
      of ARGX-113 in Patients with Primary Immune Thrombocytopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase II study in which approximately
      36 patients will be randomized in a 1:1:1 ratio to receive either ARGX-113 Dose A, or
      ARGX-113 Dose B body weight or placebo in 4 infusions administered 1-week apart in addition
      to Standard-of-Care (SoC) treatment. Patients aged 18 to 85 years (inclusive) with confirmed
      primary immune thrombocytopenia (ITP) who have a platelet count ˂ 30 × 109/L and who are
      receiving oral corticosteroids and/or permitted oral immunosuppressants and/or Thrombopoietin
      receptor (TPO-R) agonist as SoC which must be maintained on a stable dose and frequency for
      at least 4 weeks prior to Screening.

      The study will include a 2-week Screening, a 3-week Treatment period, and an 21-week
      follow-up (FU) period. The study is followed by an open label period where patients will be
      given the option to be treated with ARGX-113 Dose A in cycles of 4 weekly infusions with a
      minimum of 4 weeks apart. Patients may receive rescue therapy during the study at the
      discretion the investigator when deemed medically necessary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs).</measure>
    <time_frame>After the first administration of Investigational Medicinal Product day 1 to 30 days of a patient's last visit.</time_frame>
    <description>Changes from Baseline in vital signs, electrocardiogram parameters (ECGs), physical examination abnormalities and clinical laboratory assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and proportion of patients with initial response</measure>
    <time_frame>Over the study period (up to 13 weeks).</time_frame>
    <description>Mean change from Baseline in platelet counts</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>ARGX-113 Dose A + SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARGX-113 Dose B +SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SoC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARGX-113</intervention_name>
    <description>ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly</description>
    <arm_group_label>ARGX-113 Dose A + SoC</arm_group_label>
    <arm_group_label>ARGX-113 Dose B +SoC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly</description>
    <arm_group_label>Placebo + SoC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged ≥ 18 to ≤ 85 years.

          2. Must receive SoC treatment for ITP that has been stable in dose and frequency for at
             least 4 weeks prior to Screening. SoC may include oral corticosteroids and/or
             permitted oral immunosuppressants and/or TPO-R agonist.

          3. Confirmed diagnosis of ITP with blood platelet counts &lt; 30 × 109/L and who have not
             experienced major bleeding in the last 4 weeks prior to Screening.

        Exclusion Criteria:

          1. Use of anticoagulants, or any drug with antiplatelet effect within 3 weeks prior to
             Screening.

          2. Patients who have received any blood support or transfusion within 4 weeks prior to
             Screening.

          3. Use of Intravenous immunoglobulin G (IVIg) or anti-D immunoglobulin treatment within 4
             weeks prior to screening.

          4. Use of recombinant thrombopoietin at any time.

          5. Use of rituximab within 6 months prior to Screening. Use of any anti-CD20 other than
             rituximab at any time is not permitted.

          6. Use of immunosuppressants is not permitted within 4 weeks prior to Screening, with the
             exception of the following oral immunosuppressants: azathioprine, danazol,
             mycophenolate mofetil, mycophenolate sodium which must have been stable for at least 4
             weeks prior to Screening.

          7. Use of any other biological therapy or investigational drug than those previously
             indicated within 3 months or 5 half-lives of the drug (whichever is longer) prior to
             Screening.

          8. Received vaccinations within 4 weeks prior to Screening or planned during the study.

          9. At Screening, have clinically significant laboratory abnormalities

         10. History of any thrombotic or embolic event within 12 months prior to Screening.

         11. Known auto-immune disease other than ITP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Newland</last_name>
    <role>Study Chair</role>
    <affiliation>Barts Hospital, Cancer Centre in London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jocelyne DeWulf</last_name>
    <phone>+32 (0) 9 310 34 91</phone>
    <email>jdewulf@argenx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thierry Cousin</last_name>
    <email>tcousin@argenx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mont-Godinne</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praha</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanover</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tubingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gyula</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaposvar</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nyiregyhaza</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Opole</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wroclaw</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A Coruna</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dnipro</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nikolaev</name>
      <address>
        <city>Nikolaev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uzhgorod</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

